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Abstract 
It remains uncertain whether recurrent non-severe hypoglycemia (Hypo) results in long-term 
cognitive impairment in type 1 diabetes (T1D). Both T1D and Hypo can compromise host 
defenses against oxidative stress. This study tested the hypothesis that specifically in the T1D 
state, Hypo leads to cognitive impairment via a pathological response to oxidative stress. 
Wild-type (Control) and Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) null mice were 
studied.  Eight groups of mice (Control and Nrf2-/- ±T1D and ±Hypo) were subject to 
recurrent, twice-weekly, insulin or saline injections over 4 weeks, after which cognitive 
function was assessed and brain tissue analyzed. Recurrent moderate hypoglycemia in T1D, 
but not Control mice significantly impaired cognitive performance, and this was associated 
with hippocampal oxidative damage and inflammation despite an enhanced expression of 
Nrf2 and its target genes Hmox1 and Nqo1. In Nrf2-/-mice, both T1D and Hypo independently 
resulted in impaired cognitive performance and this was associated with oxidative cell 
damage and marked inflammation. Together, these data suggest that Hypo induces an Nrf2-
dependent antioxidant response in the hippocampus, which counteracts oxidative damage. 
However, in T1D this neuroprotective mechanism is insufficient to prevent neuronal 
oxidative damage, resulting in chronic deficits in working and long-term memory. 
Abstract Word count: 197 
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Hypoglycemia is a common adverse side effect of insulin therapy in Type 1 Diabetes (T1D), 
largely due to hyperinsulinemia, a diminished counterregulatory response, and impaired 
awareness of hypoglycemia (1). The brain is especially vulnerable to hypoglycemia due to its 
high metabolic demand and minimal fuel stores. As such, there is potential for recurrent 
hypoglycemia to produce long-term neuronal damage. This is a source of major concern and 
fear for individuals with T1D (2), especially as studies in animals and humans have yielded 
inconsistent findings. 
Profound hypoglycemia, sufficient to cause coma, results in brain damage in humans [e.g. (3; 
4)], but epidemiological studies yield conflicting data on the impact of reversible severe and 
non-severe hypoglycemia on long-term cognitive function (5). For instance, 18 years follow-
up of T1D individuals in the Diabetes Control and Complications Trial (DCCT) found no 
evidence of an association between severe hypoglycemia and cognitive decline (6). In 
contrast, prospective studies in pre-pubertal children with T1D, have reported that severe 
hypoglycemia may result in long-term neurologic damage and psychomotor retardation (7-
11). A limitation of these studies is that the cognitive decline resulting from recurrent 
hypoglycemia may take place over many decades and accurate documentation of the 
frequency of hypoglycemia over such time scales is extremely difficult. 
Studies in animal models offer the opportunity to address many of these questions over 
shorter time frames as well as to examine underlying mechanisms. This literature though is 
equally conflicting. Again, profound hypoglycemia (sufficient to induce an isoelectric EEG 
and/or multiple seizures) in animal models causes brain damage particularly in hippocampus 
and frontal cortex (12-15). However, significant neuronal damage under such conditions 
would be anticipated, and the relevance therefore to T1D where hypoglycemia of such 
severity is rare is not clear. In contrast, non-severe hypoglycemia does not appear to induce 
neuronal cell death (16) and long-term recurrent non-severe hypoglycemia has even been 
shown to protect against age-related cognitive decline (17). In addition, recurrent non-severe 
hypoglycemia in rodents potentially pre-conditions the brain protecting it to some extent from 
neurological damage resulting from subsequent very severe hypoglycemia (18). 
An additional limitation of studies in animals is that many were primarily conducted using 
non-diabetic models. This is important, because in T1D, intermittent exposure to 
hypoglycemia will always occur in the context of chronic hyperglycemia of varying degrees. 
Chronic hyperglycemia (19), severe hypoglycemia (20; 21), and glucose recovery from 
hypoglycemia (13; 22), have each independently been shown to stimulate reactive oxygen 
species (ROS) production. In addition, chronic hyperglycemia may impair antioxidant 
defense mechanisms (23-25). Therefore, the ability of neurons to respond to non-severe 
hypoglycemia may be uniquely impaired in T1D increasing vulnerability of the brain 
particularly to oxidative stress, but this question has to date not been addressed. 
To test this hypothesis, we studied insulin-treated T1D and non-diabetic rodent models that 
were exposed to intermittent episodes of non-severe hypoglycemia over 4 weeks and 
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examined the impact of these interventions on cognitive function and markers of oxidative 
stress and inflammation. Having demonstrated that recurrent hypoglycemia in T1D but not 
non-diabetic rodents induced defects in cognitive function that were associated with 
hippocampal inflammation and oxidative damage, we subsequently sought to clarify the role 
of the oxidative stress response by studying mice lacking the transcription factor Nuclear 
factor-erythroid 2 p45-related factor 2 (Nrf2) since it plays a critical role in regulating basal 
cellular antioxidant defenses as well as orchestrating responses to oxidative stress [for review 
see (26)]. Here we report that Nrf2-/- mice are very vulnerable to both T1D and recurrent 
hypoglycemia and that loss of Nrf2 resulted in strongly enhanced hippocampal inflammatory 
and oxidative damage responses to these two metabolic stimuli.   
RESEARCH DESIGN AND METHODS 
Experimental animals 
Sixty-four adult male C57BL/6J mice (20-25g; Charles River, UK) and 30 male Nrf2-/- (20-
25g) were used. Generation and genotyping of Nrf2-/- mice (kindly provided by Ken Itoh and 
Masayuki Yamamoto) have been described previously (27). Animals were fed ad libitum, on 
a 12:12h light:dark schedule. All animal procedures were approved by the University of 
Dundee Ethical Review Process and performed in accordance with UK Home Office 
regulations [under the auspices of Project Licence PIL60/4120]. 
Experimental groups 
Groups of animals were randomly assigned to receive streptozotocin (STZ; 125mg/kg 
intraperitoneally; i.p.) to induce T1D or control (citrate acid buffer i.p.). Tail vein blood 
glucose (Accuread®) was measured 3 and 7 days post-STZ and a reading ≥16.0 mmol/l (288 
mg/dl) regarded as diabetic. Animals failing to reach this were given a second injection of 
STZ and re-tested as above. Mice were subsequently sub-divided into recurrent 
hypoglycemia (Hypo) or control giving the following 4 test groups: 1) Control (Con), 2) 
Control + Hypo, 3) T1D, 4) T1D + Hypo (n=8 per group; see Supplementary Figure S1A). 
Similarly, for studies of Nrf2-null mice, animals were randomly allocated to the following 4 
test groups: 1) Nrf2-/-, 2) Nrf2-/- + Hypo, 3) T1D Nrf2-/-, 4) T1D Nrf2-/- + Hypo (n=7-8 per 
group). 
Surgery 
Animals were anesthetized by isoflurane and Linbit® insulin implants inserted 
subcutaneously. Insulin replacement was used in an attempt to replicate more closely human 
insulin-treated T1D, and to ensure the animals remained healthy and showed positive weight 
trajectory over the 12 weeks of the experiment (See Supplemental Figures, S1B and C). 
However, for the purposes of this study where the interaction between chronic hyperglycemia 
and Hypo was being explored, insulin implants at half of the recommended dose 
(~0.05U/kg/day) were used (Figure 1A and C). Control animals were also anesthetized and 
subjected to sham surgery.  
Recurrent hypoglycemia 
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Mice were subjected to 8 episodes of hypoglycemia (2 per week for 4 weeks; Figure S1A). 
Following a 4hr fast, basal glucose was measured from the tail vein and insulin was injected 
(0.75mU/g Nrf2-/-, 1mU/g Control and WT animals and 4mU/g T1D and T1D Nrf2-/-i.p.) to 
induce moderate hypoglycemia (2.5 – 3 mmol/l; Figure 1B and 1D).  Hypoglycemia was 
maintained for 2hrs and animals allowed to return to euglycemic levels with food. Animals 
were monitored continuously during the hypoglycemic period. After 2 weeks, insulin doses 
were reduced to 0.5mU/g Nrf2-/-, 0.75mU/g Control and WT animals and 2.5 - 3mU/g for 
T1D and T1D Nrf2-/- animals respectively. Any animal showing signs of physical impairment 
received glucose (1mg/kg i.p.). 2 animals in the Control group, 1 animal in the T1D group 
and 1 animal from the Nrf2-/- group required recovery on 1 occasion. Control animals were 
fasted and given saline injections. No animals suffered from seizures.  
Behavioral Procedures 
Cognition was assessed by novel object recognition (NOR) and spontaneous alternation tests 
(28; 29), at least 3 days after the last hypoglycemic episode (Figure S1A). Beckman Activity 
Box and Open field maze tasks were also made to exclude any confounding effects of altered 
activity or anxiety. 
Novel object recognition 
A simple hippocampal-mediated task based on the innate tendency of rodents to seek novelty 
was used (28). The primary outcome measure was the discrimination index (D3), calculated 
as the total time spent exploring the familiar objects/ total time spent exploring the novel 
object, for short-term (10 min) and long-term (24hr) memory. 
Spontaneous alternation 
This was used to test spatial working memory as described previously (29). Memory was 
assessed as a percent 4/5 alternation with an alternation counted when all four arms are 
visited within a span of five arm entries (29). 
Activity box  
Locomotor activity was assessed using a Beckman Activity Box. Animals, habituated to the 
box for 4 days, were placed into the box and allowed to explore freely for 15 minutes. 
Mobile, active and static counts were recorded. 
Open field maze 
Activity was recorded on film and later analysed by two independent scorers for total time 
spent within the inner and outer zones of the maze. Activity is presented as % total time spent 
in each zone.  
Biochemical analyses 
On completion of behavioral testing, animals were killed humanely, brain tissue dissected 
and flash frozen in liquid nitrogen for subsequent biochemical analyses.  
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Lipid peroxidation 
The concentration of malondialdehyde (MDA) was determined in hippocampus using the 
thiobarbituric acid reactive substances (TBARS) assay as described in (30), and adapted for a 
96-well plate format. The amount of MDA in the samples was determined 
spectrophotometrically at 532 nm and concentration determined from a standard curve. All 
samples were assayed in duplicate. 
Protein carbonylation 
Levels of carbonylated protein within the hippocampus were measured by ELISA (Caymen 
Chemicals Ltd). Protein carbonyl concentration was calculated using the following equation: 
Protein carbonyl (nmol/ml)=[(CA)/(*0.011 mM-1)](500 ml/200 ml), where CA is equal to 
the corrected absorbance (average absorbance of controls – average absorbance of samples). 
Pro-inflammatory protein array 
The total protein levels of a panel of inflammatory cytokines (IFNγ, IL-10, IL-12p70, IL-
1βIL-2, IL-4, IL-5, IL-6, KC/GRO and TNFαwere measured using the V-Plex Pro-
inflammatory Panel (mouse) kit (MSD). Hippocampal homogenates (50µg) were assayed in 
duplicate and values presented relative to their appropriate control group (Con or Nrf2-/- 
respectively).  
RNA extraction and PCR 
Total RNA was extracted from hippocampal tissue using TRIzol® reagent (Invitrogen). 
Reverse transcription was performed with 1 ng RNA using SuperScript® III First Strand 
Synthesis system for RT (Invitrogen). Real-time PCR was performed using Taqman gene 
expression assays for the following genes: Nrf2 and Nrf2 target-genes (Hmox1, Nqo1, Gsta1, 
Txn1, Txrnd1 and Srxn1(31)), the inflammatory genes Il-1β, Il-6, Tnfα, and Nos2, and house-
keeping genes (Applied Biosystems; See Supplementary Table 1 for full details of 
primer/probe sequences). All samples were performed in triplicate and normalized to Actin. 
Values are expressed as a fold-change relative to Control. 
Statistical analysis 
Data were analyzed using SPSS version 18. Multivariate analysis of variance (ANOVA) was 
used to compare groups with treatment (TID) or genotype (Nrf2-/-) and Hypo as between 
subject variables. Post-hoc analysis was performed using Tukey’s multiple comparisons test. 
Data are expressed as mean values ±SEM. Statistical significance was set at p<0.05. 
RESULTS 
Recurrent hypoglycemia in wild-type and Nrf2
-/-
 mice with or without T1D
As expected, blood glucose levels were higher in wild-type T1D compared to control animals 
over the 12-week study (Figure 1A; T1D x week F(3.74,93.48)=35.89; p<0.05). However, the 
level of hypoglycemia achieved was comparable between T1D and Control groups, (Figure 
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1B; Average glucose, Control=2.9±0.3 vs. TID=3.0±0.4 mmol/l; t=0.088; p=0.97) and did 
not change over the duration of the experiment (T1D F(1,26)=0.621; p=0.45). 
Similarly, T1D Nrf2-/- mice had significantly higher fasting glucose levels when compared to 
non-diabetic Nrf2-/- animals for the duration of the study (Figure 1C ; T1D x week 
F(3.66,36.66)= 21.53; <0.01) but the degree of hypoglycemia achieved between T1D Nrf2-/-
and Nrf2-/- animals was comparable (Figure 1D. Average glucose, Nrf2-/- =2.4±0.3 vs. 
TID Nrf2-/-=3.1±0.6 mmol/l; t=0.062, p=0.95).  
Recurrent hypoglycemia impairs cognitive function in T1D wild-type and Nrf2
-/-
mice
The most significant cognitive defect found was in long-term memory as assessed by the 
NOR task in T1D + Hypo mice (Figure 2A; T1D x Hypo; F(1,30)=5.936, p<0.05). A less 
marked cognitive defect at this time point was also found in T1D mice (Figure 2A; T1D 
F(1,30)=52.40, p<0.05), but not in control or control + Hypo animals.  These differences 
were not due to a reduction in time spent exploring the objects (effect of T1D and Hypo both 
p=ns). Performance on the NOR task after a 10min interval was intact in all groups (main 
effects T1D and Hypo on D3 indices and Exploration time; all p=ns), indicating that both the 
ability to learn the task and short-term memory for objects were intact 
On the spontaneous alternation task, T1D + Hypo animals were also most affected, 
demonstrating a reduction in percentage alternations ([Total alternations/ total entries-
4)*100] Figure 2B; T1D x Hypo (1,15)= 5.71; p<0.01) and fewer total alternations (T1D x 
HypoF(1,15)=7.734; p<0.01; Average total alternations; Control 46.29±3.66, Control + Hypo 
48.36 ±3.63, T1D 47.10±4.67, T1D + Hypo 41.67±3.80). In contrast, control animals 
receiving Hypo showed a trend towards enhanced % alternation (Figure 2B; F(1,15)=3.04; 
p=0.10). There was no effect of T1D alone on the total number of entries (F(1,30)=2.92; 
p=ns).  
As with wild-types, all Nrf2-/-animals performed the short term NOR task above chance 
levels (D3 index of ≥0.2; F<1, p=ns), and as before there were no differences between groups 
in discrimination indices and time spent exploring the objects ((D3 indices and Exploration 
time; all F<1, p=ns). However, after 24 hours, only control Nrf2-/- animals were able to 
perform the task with both Hypo, T1D and Hypo+T1D markedly impairing long-term 
memory (Figure 2C; Hypo F(1,25)=12.09, p<0.01; T1D F(1,25)=6.95, p<0.05); T1D x Hypo; 
F(1,25)=6.24, p<0.05). These differences were not due to a reduction in time spent exploring 
the objects (Exploration time; all F<1, p=ns).  
In both non-diabetic and T1D Nrf2
-/-
 animals Hypo resulted in impaired working memory 
([Total alternations/ total entries-4)*100] Figure 2D; Hypo F(1,25)=18.18; p<0.01; F<1 for 
the effect of T1D and T1D x Hypo). This impairment was accompanied by a significant 
reduction in the total number of alternations (Hypo F(1,25)=9.22, p<0.01; T1D 
F(1,25)=17.28, p<0.01; F<1, p=ns for effect of T1D x Hypo; Average total alternations; Nrf2-
/- 28.35±2.78, Nrf2-/-+ Hypo 21.00±2.80, T1D Nrf2-/-24.86±4.11, T1D Nrf2-/- + Hypo 
10.14±1.83). As with wild-type mice, there was no difference in total number of entries (T1D 
F(1,25)=4.12 p=0.776; F<1, p=ns for effect of Hypo and T1D x Hypo). 
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Assessments of locomotor activity and anxiety on the open field maze (data not shown), did 
not differ between any groups [active, mobile, or static counts (all F<1); time spent in central 
inner zone or the outer peripheral zone (all F<1)] 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to activate an 
oxidative stress response 
To explore the mechanisms underpinning the cognitive impairments demonstrated in working 
and long-term memory, transcript abundance of transcription factor Nrf2 as well as that of its 
target genes Hmox1, Nqo1, Gsta1, Txn1, Txnrd1 and Srxn1were measured in the 
hippocampus of each animal model. Significant changes in gene expression were seen in 
response to T1D and Hypo in both wild type and Nrf2-/- animals (Table 1). Both T1D and 
T1D+Hypo increased mRNA for Hmox1 and Nqo1 in all animals, while a marked increase in 
Nrf2 expression was seen in the hippocampus of T1D+Hypo wild type mice. As expected, 
the expression of other Nrf2-regulated genes (Gsta1, Txn1, Txnrd1 and Srxn1) appeared to be 
significantly diminished in all Nrf2-/-mice irrespective of the metabolic model applied.  
Interestingly, mRNA for Gsta1 was significantly decreased in response to Hypo in T1D and 
non-diabetic WT mice, and this effect was lost in Nrf2
-/-
mice (Table 1). 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to provoke 
ROS-induced cell damage in the hippocampus 
To examine for evidence of ROS induced cellular damage, levels of lipid peroxidation and 
protein carbonylation were determined in hippocampal homogenates. Hypo in both non-
diabetic and T1D mice increased lipid peroxidation within the hippocampus (Figure 3A; 
Hypo F(1,30)=8.36, p<0.05). Moreover, there was a T1D x Hypo interaction, indicating an 
additional stimulus to lipid peroxidation in T1D mice exposed to repeated hypoglycemia 
(T1D x Hypo F(1,28)=6.24 p<0.05). Protein carbonylation, an irreversible process resulting 
from exposure to ROS and an indicator of severe oxidative damage (32), was significantly 
elevated in the hippocampus only in T1D mice exposed to Hypo (Figure 3B; T1D x Hypo 
F(1,28)=4.35; p<0.05). 
In Nrf2-/-mice, hippocampal lipid peroxidation (Figure 3C) was increased by Hypo 
(F(1,25)=76.86; p<0.01), and greatest in T1D Nrf2-/- animals following Hypo (T1D x Hypo 
F(1,25)=5.07; p<0.05). Protein carbonylation was increased with Hypo (Figure 3D; Hypo 
F(1,25)=38.08; p<0.01), but not T1D (F<1, p=ns for T1D and T1D x Hypo). 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to induce an 
inflammatory response within the hippocampus 
To determine whether Hypo in T1D elicited an inflammatory response, cytokine protein 
levels were measured within hippocampal homogenates. In wild-type mice, IL-1β, IL-2, IL-4, 
IL-6 and TNFα were significantly enhanced in T1D animals whereas exposure to Hypo 
significantly increased levels of IL-12p70 and IL-5 (Table 2; all, p<0.05). The combination of 
Hypo + T1D resulted in a marked stimulus to the production of IL-1β, IL-2, TNFα, IL-4, IL-
6, IL12p70, IL-5 (Table 2; all p<.01) 
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A similar, but more marked pattern in cytokine release was seen in Nrf2-/- animals. IL-1β, IL-
2, TNFα, IL-4, IL-6, IL12p70, and IL-5 levels were increased in T1D, whereas IL-6, IL-
12p70 and IL-5 were significantly increased following Hypo (Table 2; all p< 0.05). Again, in 
Nrf2
-/-mice the combination of Hypo + T1D resulted in a marked stimulus to the production 
of IL-1β, IL-2, TNFα, IL-4, IL-6, IL12p70, IL-5 (Table 2; all p<0.001). Interestingly, levels 
of all cytokines measured were increased even in untreated Nrf2-/-mice, and amplified 
following each metabolic stimulus, although the pattern of change was nearly identical to that 
seen in wild-type mice. 
The transcript abundance of the inflammatory genes IL-1β, IL-6, Tnfα, and Nos2 were also 
checked and showed a similar pattern of change to protein levels of each cytokine, although 
these increases only reached significance in T1D and T1D+Hypo Nrf2-/- animals 
(Supplementary Table 2). 
DISCUSSION 
In this manuscript we show for the first time in a healthy insulin-treated animal model of T1D 
that recurrent non-severe hypoglycemia may impact on neuronal integrity and function. We 
show that 8 episodes of non-severe hypoglycemia in T1D over a 4-week period induces 
defects in memory consolidation and working memory, which is associated with persisting 
biochemical evidence of oxidative stress and inflammation in the hippocampus. Interestingly, 
protein synthesis, which is considered to play an integral role in memory consolidation, is 
disrupted at many levels by oxidative stress (33). In contrast and consistent with the work of 
others, recurrent hypoglycemia in non-diabetic rodents did not impair cognitive function (34). 
A key role for oxidative stress in inducing cognitive impairment was further illustrated by 
demonstrating a marked amplification of the hippocampal oxidative stress and inflammatory 
response in mice lacking the Nrf2 transcription factor (following recurrent hypoglycemia).  
Pre-clinical and clinical studies suggest that marked glycemic variability maybe detrimental 
to humans (22; 35-37). In the current study, glucose variability is represented by three 
principal metabolic states, namely chronic hyperglycemia, acute hypoglycemia, and 
‘recovery’ from acute hypoglycemia. Hypoglycemia can cause oxidative stress (20) and 
inflammation (21), and hypoglycemia-mediated ROS production can induce apoptosis (38; 
39). However, the fact that no impairment in cognitive performance was seen following Hypo 
in wild-type mice implies that the intrinsic antioxidant capacity, coupled with the oxidative 
stress response orchestrated by Nrf2, is ordinarily sufficient to protect the neuron from the 
consequences of moderate glucose deprivation. Consistent with this, recurrent hypoglycemia 
despite recovery to normal glucose levels, resulted in cognitive impairment in Nrf2
-/-
 mice. 
More recent studies in hippocampal slice preparations have shown that oxidative stress and 
neuronal death occur primarily in the recovery period from hypoglycemia during glucose 
reperfusion, and that the extent of oxidative stress correlates with the rise in glucose during 
recovery (13). In our model, glucose levels post-hypoglycemia were >16mmol/l and therefore 
glucose reperfusion into neurons that have experienced prolonged energy deprivation (as in 
ischemia reperfusion injury) may be the major contributor to oxidative stress. But Nrf2 
protein levels and function are decreased in humans and rodents with diabetes (40; 41), 
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therefore the Nrf2-mediated defense mechanism may also be insufficient to prevent oxidative 
damage resulting from non-severe hypoglycemia in T1D. Neuronal damage secondary to 
severe hypoglycemia is exacerbated in T1D rats compared with non-diabetic controls (14). 
Taken together, our data provide robust evidence that recurrent non-severe hypoglycemia in 
T1D can provoke sufficient oxidative stress to induce a local inflammatory response and 
result in neuronal dysfunction, but cannot differentiate between potential effects of 
hypoglycemia per se or recovery to hyperglycemic levels. Future studies will be required to 
address this clinically important question.   
Chronic hyperglycemia increases the production of ROS through mechanisms such as 
glucose auto-oxidation and non-enzymatic protein glycation (23), and lowers antioxidant 
defense mechanisms (24; 25) as well as serum free-radical trapping capacity (23). In the 
present study, both T1D wild-type and T1D Nrf2-/-mice demonstrated impairments in 
memory consolidation. Neither model had tissue evidence of increased lipid peroxidation or 
protein carbonylation suggesting no significant oxidative damage, but both models had 
significantly increased levels of Nrf2, Hmox-1, Nqo-1 and the inflammatory cytokines IL-1β, 
IL-2, IL-4, IL-6 and Tnfα. Intriguingly, loss of Nrf2 amplified both the inflammatory response 
and cognitive defect. It is recognized that inflammatory responses are exacerbated in Nrf2
-/-
mice (42; 43), and such an outcome is consistent in humans and rodents with diabetes where 
Nrf2 levels and activity are diminished (40; 41). This is consistent with a recognized 
hierarchical response to oxidative stressors whereby modest levels of ROS activate an Nrf2-
orchestrated adaptation whereas higher levels of ROS stimulate NF-κB and AP-1 to provide 
an additional defense mechanism (44). In this case, Nrf2-/-mice would be anticipated to have 
higher levels of ROS under both hypo- and also hyperglycemia conditions leading to a pro-
inflammatory state. Recent studies indicating a role for Nrf2 agonists in the treatment of 
diabetic nephropathy (43) and cardiomyopathy (45) that are associated with chronic 
hyperglycemia would be consistent with this possibility. The results of the present study 
would suggest that chronic hyperglycemia induces a pro-inflammatory condition through 
Nrf2-dependent and independent mechanisms.  
A critical and novel finding in this paper is the important role of the transcription factor Nrf2 
in initiating the oxidative stress response to hypoglycemia. Nrf2 is a transcription factor that 
dictates the intrinsic antioxidant capacity of cells under normal physiological conditions and 
also directs adaptation to oxidative stress. The activity of Nrf2 is itself regulated through a 
complex transcriptional/epigenetic and post-translational network in a manner that ensures its 
function increases during redox perturbation, inflammation and nutrient/energy fluxes, 
thereby enabling the factor to orchestrate adaptive responses to diverse forms of stress [for a 
review, see (26)]. Previously, Johnson and colleagues have reported that Nrf2-/- mice are 
significantly more sensitive to kainate neuronal toxicity than their wild-type counterparts, and 
used microarray analysis to show this was associated with markedly reduced expression in 
the hippocampus of aldehyde oxidase 1, Gstm1, Gstm3, peroxiredoxin 1 (Prdx1) and Prdx2 
(46). In our study, the responses of Nrf2+/+ and Nrf2-/- mice to T1D and Hypo were examined 
in separate experiments and we therefore cannot strictly compare gene expression profiles 
between wild-type and knockout mice. Nevertheless, it was apparent from our gene 
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expression analyses that large differences exist between the expression of Gsta1, Gstm1 and 
Srxn1in the hippocampus of in Nrf2
+/+
 and Nrf2
-/-
 mice. In the future, it will be desirable to 
examine simultaneously the influence that loss of Nrf2 and genetic upregulation of Nrf2 
(caused by diminished expression of Kelch-like ECH-associated protein 1 (Keap1), a 
negative regulator of Nrf2) has on gene expression and cognitive function following T1D and 
Hypo. It is notable that we found the levels of mRNA for Nrf2 were significantly upregulated 
by T1D, and very dramatically (by 12-fold) by T1D + Hypo. These results are consistent with 
a recent report that the protein levels of Nrf2 are increased in the diabetic wounds of humans 
and mice, and that pharmacological activation of Nrf2 promotes wound healing in T1D mice 
(47). Together with the heightened inflammation in T1D and T1D + HypoNrf2-/- mice 
relative to their wild-type counterparts, these findings suggest that a function of Nrf2 is to act 
as a “brake” to control inflammation. Our current results illustrate the critical importance of 
this function of Nrf2: indeed, inflammation is controlled and cognitive function is largely 
preserved in wild-type animals subjected to hypoglycemia, whereas inflammation is 
enhanced and cognitive function is severely impaired in their Nrf2
-/-
 counterparts. 
In conclusion, our study supports the hypothesis that recurrent moderate hypoglycemia in 
T1D may have long-term consequences on cognitive function. Our findings suggest that 
chronic hyperglycemia, recurrent hypoglycemia, and glucose reperfusion following 
hypoglycemia in T1D interact synergistically to induce pathological oxidative stress in 
vulnerable brain regions such as the hippocampus. Whether hypoglycemia per se or glucose 
recovery from hypoglycemia is the major contributor to oxidative damage in T1D cannot be 
determined from our studies although pre-clinical research suggests the recovery period is 
key. This has implications for clinical practice where treatment of hypoglycemia often leads 
to marked rebound hyperglycemia. Moreover, we provide evidence that the transcription 
factor Nrf2 may be integral to neuronal protection against oxidative stress during and 
following hypoglycemia, and in response to chronic hyperglycemia. This raises the 
possibility of targeting Nrf2 in developing therapies designed to prevent cellular damage in 
diabetes induced by recurrent hypoglycemia. 
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Figure Legends 
Figure 1. Physiological profile of diabetic and non-diabetic WT and Nrf2
-/-
 mice exposed 
to recurrent hypoglycemia. A and C: Body weight was comparable between experimental 
groups and unaltered by either genotype or recurrent hypoglycemia. B and D: Example of 
typical insulin induced hypoglycemic event in WT and Nrf2-/- animals with a comparable 
level of hypoglycemia achieved despite Nrf2-/- animals receiving significantly lower insulin 
doses (starting dose 0.75mU/g WT control vs. 0.5mU/g Nrf2-/- animals). Control (Con), Con 
+ Hypo, T1D and T1D + Hypo all n=8 per group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D 
Nrf2
-/- + Hypo all n=7-8 per group. Results represent mean values ± SEM. Data were 
analyzed by 2-way ANOVA with T1D and Hypo as between subject factors followed by 
Tukey’s post hoc test *p<0.05, **p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, 
♯♯p<0.01 Hypo vs. No Hypo.  
Figure 2. Recurrent hypoglycemia (Hypo) in T1D mice impairs cognitive performance 
in novel-object recognition (NOR) and Spontaneous Alternation tasks. A: Discrimination 
index (D3) demonstrating that T1D mice are significantly impaired when tested in the 24hr 
NOR task. This is exacerbated in T1D animals following Hypo. B: Mean 4/5 alternation 
performance on a closed arm plus maze, expressed as a percentage of possible alternations is 
significantly reduced in T1D animals following Hypo. C: Nrf2
-/-
 and T1D Nrf2
-/-
 mice 
following Hypo were significantly impaired when tested in the 24hr NOR task, and D: Mean 
4/5 alternation performance on a closed arm plus maze, expressed as a percentage of possible 
alternations is significantly reduced in Nrf2-/-+ Hypo and T1D Nrf2-/-+ Hypo animals when 
compared to their control (no hypo) counterparts. Control (Con), Con + Hypo, T1D and T1D 
+ Hypo all n=8 per group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- + Hypo all n=7-
8 per group. Results represent mean values ± SEM. Data were analyzed by 2-way ANOVA 
with T1D and Hypo as between subject factors followed by Tukey’s post hoc test *p<0.05 
Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo  
Figure 3. Recurrent hypoglycemia in T1D is associated with increased markers of 
oxidative damage. The levels of lipid peroxidation were determined using the thiobarbituric 
acid reactive substances (TBARS) assay and protein carbonylation by ELISA. A: The levels 
of lipid peroxidation and B: protein carbonylation were significantly elevated following Hypo 
and further enhanced in T1D mice. The levels of C. Lipid peroxidation and D: protein 
carbonylation were augmented following Hypo in Nrf2
-/-
 mice and enhanced further in T1D 
Nrf2
-/-
 + Hypo animals. Control (Con), Con + Hypo, T1D and T1D + Hypo all n=8 per group. 
Nrf2
-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- + Hypo all n=7-8 per group. Results 
represent mean values ± SEM. Data were analyzed by 2-way ANOVA with T1D and Hypo as 
between subject factors followed by Tukey’s post hoc test  *p<0.05 Control or Nrf2-/-vs T1D 
or T1D Nrf2-/-,  ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo. 
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Tables 1. Recurrent hypoglycemia and T1D in both Wild-type and Nrf2
-/-
 mice is associated with modulation of genes involved in 
mediating anti-oxidant and redox systems. mRNA was extracted and processed for real-time PCR to evaluate changes in gene expression of 
Hemeoxygenase 1 (Hmox1), Nrf2, NAD(P)H:quinoneoxidoreductase (Nqo1), Thioredoxinreductase 1 (Txnrd1), Sulfiredoxin 1 (Srxn1), 
Thioredoxin 1  (Txn1) and GlutathioneS-transferase Alpha subunit 1 (Gsta1). Control (Con), Con + Hypo, T1D and T1D + Hypo all n=8 per 
group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- + Hypo all n=7-8 per group. Results represent mean values ± SEM. Data were 
analyzed within genotype by 2-way ANOVA with T1D and Hypo as between subject factors followed by Tukey’s post hoc test *p<0.05, 
**p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo 
Gene Control Control + 
Hypo 
T1D T1D + Hypo  Nrf2-/- Nrf2-/- 
+ Hypo 
T1D Nrf2
-/- T1D Nrf2-/- 
+ Hypo 
Hmox-1 1.00±0.28 1.15±0.14 1.34±0.14* 1.88±0.55*
♯  0.71±0.07 0.49±0.08 1.05±0.11** 1.15±0.11**♯ 
Nrf2 1.00±0.15 1.14±0.18 1.86±0.18* 12.13±0.10*
♯  n/d n/d n/d n/d 
Nqo1 1.00±0.35 1.53±0.17 2.11±0.28* 3.20±0.44*
♯  1.94±0.13 1.78±0.12 2.18±0.31* 2.74±0.24*♯ 
Txnrd1 1.00±0.19 1.07±0.10 1.08±0.10 1.09±0.13  0.79±0.05 0.95±0.12 0.60±0.08 0.59±0.05 
Srxn1 1.00±0.09 0.94±0.06 1.06±0.03 1.13±0.14  0.58±0.10 0.71±0.16 0.43±0.05 0.48±0.04 
Txn1 1.00±0.16 0.96±0.11 1.28±0.19 1.32±0.23  0.82±0.06 0.74±0.11 0.73±0.11 0.76±0.11 
Gsta1 1.00±0.13 0.50±0.76
♯ 1.00±0.06 0.53±0.16♯  0.11±0.04 0.22±0.07 0.10±0.04 0.10±0.04 
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Table 2. Recurrent hypoglycemia and T1D induce inflammation within the hippocampus in both WT T1D animals and Nrf2
-/-
animals 
respectively. Levels of a number of common inflammatory cytokines were measured within hippocampal homogenates by ELISA. Con, Con + 
Hypo, T1D and T1D + Hypo all n=8 per group.  Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/-+ Hypo all n=7-8 per group.  Results 
represent mean values ± SEM. Data were analyzed within genotype by 2-way ANOVA with T1D and Hypo as between subject factors followed 
by Tukey’s post hoc test * p<0.05, test *p<0.05, **p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo. 
Protein 
(pg/mg) 
Control Control + 
Hypo 
T1D T1D + Hypo  Nrf2-/- Nrf2-/- 
+ Hypo 
T1D Nrf2
-/- T1D Nrf2-/- 
+ Hypo 
IFNg 1.26±0.19 1.01±0.19 1.21±0.19 1.16±0.29  2.04 ±0.13 1.99±0.24 1.97±0.21 1.73±0.30 
KC/GRO 57.60±7.42 68.86±10.73 65.15±9.51 59.57±7.03  99.49±7.24 95.35±12.47 102.7±12.12 116.7±21.47 
IL-1b 1.63±0.14 1.72±0.26 2.68±0.25** 3.15±0.43**
♯  2.96±0.49 2.62±0.39 6.95±0.80* 9.40±1.23*♯ 
IL-2 5.20±1.10 6.19±0.93 6.80±1.27* 10.72±1.23*
♯  6.47±0.76 7.10±1.10 10.91±1.15** 10.88±0.86**♯ 
TNFa 1.87±0.45 1.39±0.73 4.28±0.44* 7.37±0.61**
♯  4.97±0.86 7.34±1.40 10.41±2.28* 10.75±1.98*♯ 
IL-4 1.56±0.26 1.32±0.26 3.05±0.52** 4.35±0.34**
♯  2.16±0.32 3.28±0.53 4.96±0.58** 5.34±0.57**♯ 
IL-6 85.54±13.29 106.4±16.11 146.8±17.30** 178.3±9.32**
♯  99.48±11.59 140.4±3.99♯ 145.4±8.58** 149.6±6.88**♯ 
IL-12p70 20.20±1.31 25.84±1.15
♯ 24.83±1.71 27.65±02.09*♯  20.00±3.25 27.63±2.83♯♯ 22.02±3.84* 35.23±4.27*♯♯ 
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IL-5 5.39±0.68 7.17±0.41
♯ 5.11±0.69 8.48±0.74*♯♯  5.48±0.66 6.78±0.31♯ 8.45±0.59** 7.58±0.22**♯ 
 
 
 
 
 
 
 
 
 
. 
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Abstract 
It remains uncertain whether recurrent non-severe hypoglycemia (Hypo) results in long-term 
cognitive impairment in type 1 diabetes (T1D). Both T1D and Hypo can compromise host 
defenses against oxidative stress. This study tested the hypothesis that specifically in the T1D 
state, Hypo leads to cognitive impairment via a pathological response to oxidative stress. 
Wild-type (Control) and Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) null mice were 
studied.  Eight groups of mice (Control and Nrf2-/- ±T1D and ±Hypo) were subject to 
recurrent, twice-weekly, insulin or saline injections over 4 weeks, after which cognitive 
function was assessed and brain tissue analyzed. Recurrent moderate hypoglycemia in T1D, 
but not Control mice significantly impaired cognitive performance, and this was associated 
with hippocampal oxidative damage and inflammation despite an enhanced expression of 
Nrf2 and its target genes Hmox1 and Nqo1. In Nrf2-/-mice, both T1D and Hypo independently 
resulted in impaired cognitive performance and this was associated with oxidative cell 
damage and marked inflammation. Together, these data suggest that Hypo induces an Nrf2-
dependent antioxidant response in the hippocampus, which counteracts oxidative damage. 
However, in T1D this neuroprotective mechanism is insufficient to prevent neuronal 
oxidative damage, resulting in chronic deficits in working and long-term memory. 
 
Abstract Word count: 197 
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Hypoglycemia is a common adverse side effect of insulin therapy in Type 1 Diabetes (T1D), 
largely due to hyperinsulinemia, a diminished counterregulatory response, and impaired 
awareness of hypoglycemia (1). The brain is especially vulnerable to hypoglycemia due to its 
high metabolic demand and minimal fuel stores. As such, there is potential for recurrent 
hypoglycemia to produce long-term neuronal damage. This is a source of major concern and 
fear for individuals with T1D (2), especially as studies in animals and humans have yielded 
inconsistent findings. 
Profound hypoglycemia, sufficient to cause prolonged coma, results in brain damage in 
humans [e.g. (3; 4)], but epidemiological studies yield conflicting data on the impact of 
reversible severe and non-severe hypoglycemia on long-term cognitive function (5). For 
instance, 18 years follow-up of T1D individuals in the Diabetes Control and Complications 
Trial (DCCT) found no evidence of an association between severe hypoglycemia and 
cognitive decline (6). In contrast, prospective studies in pre-pubertal children with T1D, have 
reported that severe hypoglycemia may result in long-term neurologic damage and 
psychomotor retardation (7-11). A limitation of these studies is that the cognitive decline 
resulting from recurrent hypoglycemia may take place over many decades and accurate 
documentation of the frequency of hypoglycemia over such time scales is extremely difficult. 
Studies in animal models offer the opportunity to address many of these questions over 
shorter time frames as well as to examine underlying mechanisms. This literature though is 
equally conflicting. Again, profound hypoglycemia (sufficient to induce an isoelectric EEG 
and/or multiple seizures) in animal models causes brain damage particularly in hippocampus 
and frontal cortex (12-15). However, significant neuronal damage under such conditions 
would be anticipated, and the relevance therefore to T1D where hypoglycemia of such 
severity is rare is not clear. In contrast, non-severe hypoglycemia does not appear to induce 
neuronal cell death (16) and long-term recurrent non-severe hypoglycemia has even been 
shown to protect against age-related cognitive decline (17). In addition, recurrent non-severe 
hypoglycemia in rodents potentially pre-conditions the brain protecting it to some extent from 
neurological damage resulting from subsequent very severe hypoglycemia (18). 
An additional limitation of studies in animals is that many were primarily conducted using 
non-diabetic models. This is important, because in T1D, intermittent exposure to 
hypoglycemia will always occur in the context of chronic hyperglycemia of varying degrees. 
Chronic hyperglycemia (19), severe hypoglycemia (20; 21), and glucose recovery from 
hypoglycemia (13; 22), have each independently been shown to stimulate reactive oxygen 
species (ROS) production. In addition, chronic hyperglycemia may impair antioxidant 
defense mechanisms (23-25). Therefore, the ability of neurons to respond to non-severe 
hypoglycemia may be uniquely impaired in T1D increasing vulnerability of the brain 
particularly to oxidative stress, but this question has to date not been addressed. 
To test this hypothesis, we studied insulin-treated T1D and non-diabetic rodent models that 
were exposed to intermittent episodes of non-severe hypoglycemia over 4 weeks and 
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examined the impact of these interventions on cognitive function and markers of oxidative 
stress and inflammation. Having demonstrated that recurrent hypoglycemia in T1D but not 
non-diabetic rodents induced defects in cognitive function that were associated with 
hippocampal inflammation and oxidative damage, we subsequently sought to clarify the role 
of the oxidative stress response by studying mice lacking the transcription factor Nuclear 
factor-erythroid 2 p45-related factor 2 (Nrf2) since it plays a critical role in regulating basal 
cellular antioxidant defenses as well as orchestrating responses to oxidative stress [for review 
see (26)]. Here we report that Nrf2-/- mice are very vulnerable to both T1D and recurrent 
hypoglycemia and that loss of Nrf2 resulted in strongly enhanced hippocampal inflammatory 
and oxidative damage responses to these two metabolic stimuli.   
RESEARCH DESIGN AND METHODS 
Experimental animals 
Sixty-four adult male C57BL/6J mice (20-25g; Charles River, UK) and 30 male Nrf2-/- (20-
25g) were used. Generation and genotyping of Nrf2-/- mice (kindly provided by Ken Itoh and 
Masayuki Yamamoto) have been described previously (27). Animals were fed ad libitum, on 
a 12:12h light:dark schedule. All animal procedures were approved by the University of 
Dundee Ethical Review Process and performed in accordance with UK Home Office 
regulations [under the auspices of Project Licence PIL60/4120]. 
Experimental groups 
Groups of animals were randomly assigned to receive streptozotocin (STZ; 125mg/kg 
intraperitoneally; i.p.) to induce T1D or control (citrate acid buffer i.p.). Tail vein blood 
glucose (Accuread®) was measured 3 and 7 days post-STZ and a reading ≥16.0 mmol/l (288 
mg/dl) regarded as diabetic. Animals failing to reach this were given a second injection of 
STZ and re-tested as above. Mice were subsequently sub-divided into recurrent 
hypoglycemia (Hypo) or control giving the following 4 test groups: 1) Control (Con), 2) 
Control + Hypo, 3) T1D, 4) T1D + Hypo (n=8 per group; see Supplementary Figure S1A). 
Similarly, for studies of Nrf2-null mice, animals were randomly allocated to the following 4 
test groups: 1) Nrf2-/-, 2) Nrf2-/- + Hypo, 3) T1D Nrf2-/-, 4) T1D Nrf2-/- + Hypo (n=7-8 per 
group). 
Surgery  
Animals were anesthetized by isoflurane and Linbit® insulin implants inserted 
subcutaneously. Insulin replacement was used in an attempt to replicate more closely human 
insulin-treated T1D, and to ensure the animals remained healthy and showed positive weight 
trajectory over the 12 weeks of the experiment (See Supplemental Figures, S1B and C). 
However, for the purposes of this study where the interaction between chronic hyperglycemia 
and Hypo was being explored, insulin implants at half of the recommended dose 
(~0.05U/kg/day) were used (Figure 1A and C). Control animals were also anesthetized and 
subjected to sham surgery.  
Recurrent hypoglycemia 
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Mice were subjected to 8 episodes of hypoglycemia (2 per week for 4 weeks; Figure S1A). 
Following a 4hr fast, basal glucose was measured from the tail vein and insulin was injected 
(0.75mU/g Nrf2-/-, 1mU/g Control and WT animals and 4mU/g T1D and T1D Nrf2-/-i.p.) to 
induce moderate hypoglycemia (2.5 – 3 mmol/l; Figure 1B and 1D).  Hypoglycemia was 
maintained for 2hrs and animals allowed to return to euglycemic levels with food. Animals 
were monitored continuously during the hypoglycemic period. After 2 weeks, insulin doses 
were reduced to 0.5mU/g Nrf2-/-, 0.75mU/g Control and WT animals and 2.5 - 3mU/g for 
T1D and T1D Nrf2-/- animals respectively. Any animal not eating or showing signs of 
locomotor/physical impairment received glucose (1mg/kg i.p.). In total 2 animals in the 
Control group, 1 animal in the T1D group and 1 animal from the Nrf2-/- group required 
recovery on 1 or more occasions. Control animals were fasted and given saline injections. No 
animals suffered from seizures.  
Behavioral Procedures 
Cognition was assessed by novel object recognition (NOR) and spontaneous alternation tests 
(28; 29), at least 3 days after the last hypoglycemic episode (Figure S1A). Beckman Activity 
Box and Open field maze tasks were also made to exclude any confounding effects of altered 
activity or anxiety. 
Novel object recognition 
A simple hippocampal-mediated task based on the innate tendency of rodents to seek novelty 
was used (28). The primary outcome measure was the discrimination index (D3), calculated 
as the total time spent exploring the familiar objects/ total time spent exploring the novel 
object, for short-term (10 min) and long-term (24hr) memory. 
Spontaneous alternation 
This was used to test spatial working memory as described previously (29). Memory was 
assessed as a percent 4/5 alternation with an alternation counted when all four arms are 
visited within a span of five arm entries (29). 
Activity box  
Locomotor activity was assessed using a Beckman Activity Box. Animals, habituated to the 
box for 4 days, were placed into the box and allowed to explore freely for 15 minutes. 
Mobile, active and static counts were recorded. 
Open field maze 
Activity was recorded on film and later analysed by two independent scorers for total time 
spent within the inner and outer zones of the maze. Activity is presented as % total time spent 
in each zone.  
Biochemical analyses 
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On completion of behavioral testing, animals were killed humanely, brain tissue dissected 
and flash frozen in liquid nitrogen for subsequent biochemical analyses.  
Lipid peroxidation 
The concentration of malondialdehyde (MDA) was determined in hippocampus using the 
thiobarbituric acid reactive substances (TBARS) assay as described in (30), and adapted for a 
96-well plate format. The amount of MDA in the samples was determined 
spectrophotometrically at 532 nm and concentration determined from a standard curve. All 
samples were assayed in duplicate. 
Protein carbonylation 
Levels of carbonylated protein within the hippocampus were measured by ELISA (Caymen 
Chemicals Ltd). Protein carbonyl concentration was calculated using the following equation: 
Protein carbonyl (nmol/ml)=[(CA)/(*0.011 mM-1)](500 ml/200 ml), where CA is equal to 
the corrected absorbance (average absorbance of controls – average absorbance of samples). 
Pro-inflammatory protein array 
The total protein levels of a panel of inflammatory cytokines (IFNγ, IL-10, IL-12p70, IL-
1βIL-2, IL-4, IL-5, IL-6, KC/GRO and TNFαwere measured using the V-Plex Pro-
inflammatory Panel (mouse) kit (MSD). Hippocampal homogenates (50µg) were assayed in 
duplicate and values presented relative to their appropriate control group (Con or Nrf2-/- 
respectively).  
RNA extraction and PCR 
Total RNA was extracted from hippocampal tissue using TRIzol® reagent (Invitrogen). 
Reverse transcription was performed with 1 ng RNA using SuperScript® III First Strand 
Synthesis system for RT (Invitrogen). Real-time PCR was performed using Taqman gene 
expression assays for the following genes: Nrf2 and Nrf2 target-genes (Hmox1, Nqo1, Gsta1, 
Txn1, Txrnd1 and Srxn1(31)), the inflammatory genes Il-1β, Il-6, Tnfα, and Nos2, and house-
keeping genes (Applied Biosystems; See Supplementary Table 1 for full details of 
primer/probe sequences). All samples were performed in triplicate and normalized to Actin. 
Values are expressed as a fold-change relative to Control. 
Statistical analysis 
Data were analyzed using SPSS version 18. Multivariate analysis of variance (ANOVA) was 
used to compare groups with treatment (TID) or genotype (Nrf2-/-) and Hypo as between 
subject variables. Post-hoc analysis was performed using Tukey’s multiple comparisons test. 
Data are expressed as mean values ±SEM. Statistical significance was set at p<0.05. 
RESULTS 
Recurrent hypoglycemia in wild-type and Nrf2
-/-
 mice with or without T1D 
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As expected, blood glucose levels were higher in wild-type T1D compared to control animals 
over the 12-week study (Figure 1A; T1D x week F(3.74,93.48)=35.89; p<0.05). However, the 
level of hypoglycemia achieved was comparable between T1D and Control groups, (Figure 
1B; Average glucose, Control=2.9±0.3 vs. TID=3.0±0.4 mmol/l; t=0.088; p=0.97) and did 
not change over the duration of the experiment (T1D F(1,26)=0.621; p=0.45). 
Similarly, T1D Nrf2-/- mice had significantly higher fasting glucose levels when compared to 
non-diabetic Nrf2-/- animals for the duration of the study (Figure 1C ; T1D x week 
F(3.66,36.66)= 21.53; <0.01) but the degree of hypoglycemia achieved between T1D Nrf2-/-
 and Nrf2-/- animals was comparable (Figure 1D. Average glucose, Nrf2-/- =2.4±0.3 vs. 
TID Nrf2-/-=3.1±0.6 mmol/l; t=0.062, p=0.95).  
Recurrent hypoglycemia impairs cognitive function in T1D wild-type and Nrf2
-/-
mice 
The most significant cognitive defect found was in long-term memory as assessed by the 
NOR task in T1D + Hypo mice (Figure 2A; T1D x Hypo; F(1,30)=5.936, p<0.05). A less 
marked cognitive defect at this time point was also found in T1D mice (Figure 2A; T1D 
F(1,30)=52.40, p<0.05), but not in control or control + Hypo animals.  These differences 
were not due to a reduction in time spent exploring the objects (effect of T1D and Hypo both 
p=ns). Performance on the NOR task after a 10min interval was intact in all groups (main 
effects T1D and Hypo on D3 indices and Exploration time; all p=ns), indicating that both the 
ability to learn the task and short-term memory for objects were intact 
On the spontaneous alternation task, T1D + Hypo animals were also most affected, 
demonstrating a reduction in percentage alternations ([Total alternations/ total entries-
4)*100] Figure 2B; T1D x Hypo (1,15)= 5.71; p<0.01) and fewer total alternations (T1D x 
HypoF(1,15)=7.734; p<0.01; Average total alternations; Control 46.29±3.66, Control + Hypo 
48.36 ±3.63, T1D 47.10±4.67, T1D + Hypo 41.67±3.80). In contrast, control animals 
receiving Hypo showed a trend towards enhanced % alternation (Figure 2B; F(1,15)=3.04; 
p=0.10). There was no effect of T1D alone on the total number of entries (F(1,30)=2.92; 
p=ns).  
As with wild-types, all Nrf2-/-animals performed the short term NOR task above chance 
levels (D3 index of ≥0.2; F<1, p=ns), and as before there were no differences between groups 
in discrimination indices and time spent exploring the objects ((D3 indices and Exploration 
time; all F<1, p=ns). However, after 24 hours, only control Nrf2
-/-
 animals were able to 
perform the task with both Hypo, T1D and Hypo+T1D markedly impairing long-term 
memory (Figure 2C; Hypo F(1,25)=12.09, p<0.01; T1D F(1,25)=6.95, p<0.05); T1D x Hypo; 
F(1,25)=6.24, p<0.05). These differences were not due to a reduction in time spent exploring 
the objects (Exploration time; all F<1, p=ns).  
In both non-diabetic and T1D Nrf2-/- animals Hypo resulted in impaired working memory 
([Total alternations/ total entries-4)*100] Figure 2D; Hypo F(1,25)=18.18; p<0.01; F<1 for 
the effect of T1D and T1D x Hypo). This impairment was accompanied by a significant 
reduction in the total number of alternations (Hypo F(1,25)=9.22, p<0.01; T1D 
F(1,25)=17.28, p<0.01; F<1, p=ns for effect of T1D x Hypo; Average total alternations; Nrf2-
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/-
  28.35±2.78, Nrf2
-/-
+ Hypo 21.00±2.80, T1D Nrf2
-/-
24.86±4.11, T1D Nrf2
-/-
 + Hypo 
10.14±1.83). As with wild-type mice, there was no difference in total number of entries (T1D 
F(1,25)=4.12 p=0.776; F<1, p=ns for effect of Hypo and T1D x Hypo). 
Assessments of locomotor activity and anxiety on the open field maze (data not shown), did 
not differ between any groups [active, mobile, or static counts (all F<1); time spent in central 
inner zone or the outer peripheral zone (all F<1)] 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to activate an 
oxidative stress response 
To explore the mechanisms underpinning the cognitive impairments demonstrated in working 
and long-term memory, transcript abundance of transcription factor Nrf2 as well as that of its 
target genes Hmox1, Nqo1, Gsta1, Txn1, Txnrd1 and Srxn1were measured in the 
hippocampus of each animal model. Significant changes in gene expression were seen in 
response to T1D and Hypo in both wild type and Nrf2-/- animals (Table 1). Both T1D and 
T1D+Hypo increased mRNA for Hmox1 and Nqo1 in all animals, while a marked increase in 
Nrf2 expression was seen in the hippocampus of T1D+Hypo wild type mice. As expected, 
the expression of other Nrf2-regulated genes (Gsta1, Txn1, Txnrd1 and Srxn1) appeared to be 
significantly diminished in all Nrf2
-/-
mice irrespective of the metabolic model applied.  
Interestingly, mRNA for Gsta1 was significantly decreased in response to Hypo in T1D and 
non-diabetic WT mice, and this effect was lost in Nrf2-/-mice (Table 1). 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to provoke 
ROS-induced cell damage in the hippocampus 
To examine for evidence of ROS induced cellular damage, levels of lipid peroxidation and 
protein carbonylation were determined in hippocampal homogenates. Hypo in both non-
diabetic and T1D mice increased lipid peroxidation within the hippocampus (Figure 3A; 
Hypo F(1,30)=8.36, p<0.05). Moreover, there was a T1D x Hypo interaction, indicating an 
additional stimulus to lipid peroxidation in T1D mice exposed to repeated hypoglycemia 
(T1D x Hypo F(1,28)=6.24 p<0.05). Protein carbonylation, an irreversible process resulting 
from exposure to ROS and an indicator of severe oxidative damage (32), was significantly 
elevated in the hippocampus only in T1D mice exposed to Hypo (Figure 3B; T1D x Hypo 
F(1,28)=4.35; p<0.05). 
In Nrf2
-/-
mice, hippocampal lipid peroxidation (Figure 3C) was increased by Hypo 
(F(1,25)=76.86; p<0.01), and greatest in T1D Nrf2
-/-
 animals following Hypo (T1D x Hypo 
F(1,25)=5.07; p<0.05). Protein carbonylation was increased with Hypo (Figure 3D; Hypo 
F(1,25)=38.08; p<0.01), but not T1D (F<1, p=ns for T1D and T1D x Hypo). 
Recurrent hypoglycemia and chronic hyperglycemia act synergistically to induce an 
inflammatory response within the hippocampus 
To determine whether Hypo in T1D elicited an inflammatory response, cytokine protein 
levels were measured within hippocampal homogenates. In wild-type mice, IL-1β, IL-2, IL-4, 
IL-6 and TNFα were significantly enhanced in T1D animals whereas exposure to Hypo 
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significantly increased levels of IL-12p70 and IL-5 (Table 2; all, p<0.05). The combination of 
Hypo + T1D resulted in a marked stimulus to the production of IL-1β, IL-2, TNFα, IL-4, IL-
6, IL12p70, IL-5 (Table 2; all p<.01) 
A similar, but more marked pattern in cytokine release was seen in Nrf2-/- animals. IL-1β, IL-
2, TNFα, IL-4, IL-6, IL12p70, and IL-5 levels were increased in T1D, whereas IL-6, IL-
12p70 and IL-5 were significantly increased following Hypo (Table 2; all p< 0.05). Again, in 
Nrf2
-/-mice the combination of Hypo + T1D resulted in a marked stimulus to the production 
of IL-1β, IL-2, TNFα, IL-4, IL-6, IL12p70, IL-5 (Table 2; all p<0.001). Interestingly, levels 
of all cytokines measured were increased even in untreated Nrf2
-/-
mice, and amplified 
following each metabolic stimulus, although the pattern of change was nearly identical to that 
seen in wild-type mice. 
The transcript abundance of the inflammatory genes IL-1β, IL-6, Tnfα, and Nos2 were also 
checked and showed a similar pattern of change to protein levels of each cytokine, although 
these increases only reached significance in T1D and T1D+Hypo Nrf2-/- animals 
(Supplementary Table 2). 
DISCUSSION 
In this manuscript we show for the first time in a healthy insulin-treated animal model of T1D 
that recurrent non-severe hypoglycemia may have a significant impact on neuronal integrity 
and function. We show that 8 episodes of non-severe hypoglycemia in T1D over a 4-week 
period induces significant defects in memory consolidation and working memory, and that 
this is associated with persisting biochemical evidence of oxidative stress and inflammation 
in the hippocampus. Interestingly, protein synthesis, which is considered to play an integral 
role in memory consolidation, is disrupted at many levels by oxidative stress (33). In contrast 
and consistent with the work of others, recurrent hypoglycemia in non-diabetic rodents did 
not impair cognitive function and may even have improved cognitive performance (34). The 
key role for oxidative stress in inducing cognitive impairment was further illustrated in the 
demonstration of a marked amplification of the hippocampal oxidative stress and 
inflammatory response in mice lacking the Nrf2 transcription factor (following recurrent 
hypoglycemia).  
Pre-clinical and clinical studies suggest that marked glycemic variability maybe detrimental 
to humans (22; 35-37). In the current study, glucose variability is represented by three 
principal metabolic states, namely chronic hyperglycemia, acute hypoglycemia, and 
‘recovery’ from acute hypoglycemia. Hypoglycemia can cause oxidative stress (20) and 
inflammation (21), and hypoglycemia-mediated ROS production can induce apoptosis (38; 
39). However, the fact that no impairment in cognitive performance was seen following Hypo 
in wild-type mice implies that the intrinsic antioxidant capacity, coupled with the oxidative 
stress response orchestrated by Nrf2, is ordinarily sufficient to protect the neuron from the 
consequences of moderate glucose deprivation. Consistent with this, recurrent hypoglycemia 
despite recovery to normal glucose levels, resulted in cognitive impairment in Nrf2
-/-
 mice. 
More recent studies in hippocampal slice preparations have shown that oxidative stress and 
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neuronal death occur primarily in the recovery period from hypoglycemia during glucose 
reperfusion, and that the extent of oxidative stress correlates with the rise in glucose during 
recovery (13). In our model, glucose levels post-hypoglycemia were >16mmol/l and therefore 
glucose reperfusion into neurons that have experienced prolonged energy deprivation (as in 
ischemia reperfusion injury) may be the major contributor to oxidative stress. But Nrf2 
protein levels and function are decreased in humans and rodents with diabetes (40; 41), 
therefore the Nrf2-mediated defense mechanism may also be insufficient to prevent oxidative 
damage resulting from non-severe hypoglycemia in T1D. Neuronal damage secondary to 
severe hypoglycemia is exacerbated in T1D rats compared with non-diabetic controls (14). 
Taken together, our data provide robust evidence that recurrent non-severe hypoglycemia in 
T1D can provoke sufficient oxidative stress to induce a local inflammatory response and 
result in neuronal dysfunction, but cannot differentiate between potential effects of 
hypoglycemia per se or recovery to hyperglycemic levels. Future studies will be required to 
address this clinically important question.   
Chronic hyperglycemia increases the production of ROS through mechanisms such as 
glucose auto-oxidation and non-enzymatic protein glycation (23), and lowers antioxidant 
defense mechanisms (24; 25) as well as serum free-radical trapping capacity (23). In the 
present study, both T1D wild-type and T1D Nrf2-/-mice demonstrated impairments in 
memory consolidation. Neither model had tissue evidence of increased lipid peroxidation or 
protein carbonylation suggesting no significant oxidative damage, but both models had 
significantly increased levels of Nrf2, Hmox-1, Nqo-1 and the inflammatory cytokines IL-1β, 
IL-2, IL-4, IL-6 and Tnfα. Intriguingly, loss of Nrf2 amplified both the inflammatory response 
and cognitive defect. It is recognized that inflammatory responses are exacerbated in Nrf2-/-
mice (42; 43), and such an outcome is consistent in humans and rodents with diabetes where 
Nrf2 levels and activity are diminished (40; 41). This is consistent with a recognized 
hierarchical response to oxidative stressors whereby modest levels of ROS activate an Nrf2-
orchestrated adaptation whereas higher levels of ROS stimulate NF-κB and AP-1 to provide 
an additional defense mechanism (44). In this case, Nrf2-/-mice would be anticipated to have 
higher levels of ROS under both hypo- and also hyperglycemia conditions leading to a pro-
inflammatory state. Recent studies indicating a role for Nrf2 agonists in the treatment of 
diabetic nephropathy (43) and cardiomyopathy (45) that are associated with chronic 
hyperglycemia would be consistent with this possibility. The results of the present study 
would suggest that chronic hyperglycemia induces a pro-inflammatory condition through 
Nrf2-dependent and independent mechanisms.  
A critical and novel finding in this paper is the important role of the transcription factor Nrf2 
in initiating the oxidative stress response to hypoglycemia. Nrf2 is a transcription factor that 
dictates the intrinsic antioxidant capacity of cells under normal physiological conditions and 
also directs adaptation to oxidative stress. The activity of Nrf2 is itself regulated through a 
complex transcriptional/epigenetic and post-translational network in a manner that ensures its 
function increases during redox perturbation, inflammation and nutrient/energy fluxes, 
thereby enabling the factor to orchestrate adaptive responses to diverse forms of stress [for a 
review, see (26)]. Previously, Johnson and colleagues have reported that Nrf2-/- mice are 
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significantly more sensitive to kainate neuronal toxicity than their wild-type counterparts, and 
used microarray analysis to show this was associated with markedly reduced expression in 
the hippocampus of aldehyde oxidase 1, Gstm1, Gstm3, peroxiredoxin 1 (Prdx1) and Prdx2 
(46). In our study, the responses of Nrf2+/+ and Nrf2-/- mice to T1D and Hypo were examined 
in separate experiments and we therefore cannot strictly compare gene expression profiles 
between wild-type and knockout mice. Nevertheless, it was apparent from our gene 
expression analyses that large differences exist between the expression of Gsta1, Gstm1 and 
Srxn1in the hippocampus of in Nrf2+/+ and Nrf2-/- mice. In the future, it will be desirable to 
examine simultaneously the influence that loss of Nrf2 and genetic upregulation of Nrf2 
(caused by diminished expression of Kelch-like ECH-associated protein 1 (Keap1), a 
negative regulator of Nrf2) has on gene expression and cognitive function following T1D and 
Hypo. It is notable that we found the levels of mRNA for Nrf2 were significantly upregulated 
by T1D, and very dramatically (by 12-fold) by T1D + Hypo. These results are consistent with 
a recent report that the protein levels of Nrf2 are increased in the diabetic wounds of humans 
and mice, and that pharmacological activation of Nrf2 promotes wound healing in T1D mice 
(47). Together with the heightened inflammation in T1D and T1D + HypoNrf2
-/-
 mice 
relative to their wild-type counterparts, these findings suggest that one of the functions of 
Nrf2 is to act as a “brake” to control inflammation. Our current results illustrate the critical 
importance of this function of Nrf2: indeed, inflammation is controlled and cognitive 
function is largely preserved in wild-type animals subjected to hypoglycemia, whereas 
inflammation is enhanced and cognitive function is severely impaired in their Nrf2-/- 
counterparts. 
In conclusion, our study supports the hypothesis that recurrent moderate hypoglycemia in 
T1D may have long-term consequences on cognitive function. Our findings suggest that 
chronic hyperglycemia, recurrent hypoglycemia, and glucose reperfusion following 
hypoglycemia in T1D interact synergistically to induce pathological oxidative stress in 
vulnerable brain regions such as the hippocampus. Whether hypoglycemia per se or glucose 
recovery from hypoglycemia is the major contributor to oxidative damage in T1D cannot be 
determined from our studies although pre-clinical research suggests the recovery period is 
key. This has implications for clinical practice where treatment of hypoglycemia often leads 
to marked rebound hyperglycemia. Moreover, we provide evidence that the transcription 
factor Nrf2 may be integral to neuronal protection against oxidative stress during and 
following hypoglycemia, and in response to chronic hyperglycemia. This raises the 
possibility of targeting Nrf2 in developing therapies designed to prevent cellular damage in 
diabetes induced by recurrent hypoglycemia. 
 
 
Acknowledgements 
Page 32 of 48
For Peer Review Only
Diabetes
 12
Funding:  This work was supported by an award from the University of Dundee/ Wellcome 
Trust Translational Medical Research Fund (RJM), Diabetes UK (12/0004531) and Juvenile 
Diabetes Research Foundation (5-2011-464). 
 
Author Contributions: A.D.M. designed and performed experiments and wrote manuscript. 
J.R.G. performed experiments. A.T.D-K. contributed to discussion and reviewed /edited 
manuscript. J.D.H. contributed to discussion and reviewed /edited manuscript. M.L.J.A. 
contributed to discussion and reviewed /edited manuscript. J.S. contributed to design of 
experiments and discussion and research reviewed /edited manuscript. R.J.M designed 
experiments and wrote manuscript. R.J.M. is overall guarantor for the contents of the article. 
 
 
  
Page 33 of 48
For Peer Review Only
Diabetes
 13
References 
1. McCrimmon RJ, Sherwin RS: Hypoglycemia in type 1 diabetes. Diabetes 2010;59:2333-2339 
2. McCrimmon RJ, Frier BM: Hypoglycaemia: the most feared complication of insulin therapy. 
Diabete & Metabolisme 1994;20:503-512 
3. Chalmers J, Risk MT, Kean DM, Grant R, Ashworth B, Campbell IW: Severe amnesia after 
hypoglycemia. Clinical, psychometric, and magnetic resonance imaging correlations. Diabetes Care 
1991;14:922-925 
4. Fujioka M, Okuchi K, Hiramatsu KI, Sakaki T, Sakaguchi S, Ishii Y: Specific changes in human brain 
after hypoglycemic injury. Stroke; a journal of cerebral circulation 1997;28:584-587 
5. McCrimmon RJ, Ryan CM, Frier BM: Diabetes and cognitive dysfunction. Lancet 2012;379:2291-
2299 
6. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Study Research G, Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, 
Burwood A, Weinger K, Bayless M, Dahms W, Harth J: Long-term effect of diabetes and its treatment 
on cognitive function. New England Journal of Medicine 2007;356:1842-1852 
7. Hershey T, Perantie DC, Warren SL, Zimmerman EC, Sadler M, White NH: Frequency and timing of 
severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes care 
2005;28:2372-2377 
8. Ryan CM, Atchison J, Puczynski S, Puczynski M, Arslanian S, Becker D: Mild hypoglycemia 
associated with deterioration of mental efficiency in children with insulin-dependent diabetes 
mellitus. The Journal of pediatrics 1990;117:32-38 
9. Patino-Fernandez AM, Delamater AM, Applegate EB, Brady E, Eidson M, Nemery R, Gonzalez-
Mendoza L, Richton S: Neurocognitive functioning in preschool-age children with type 1 diabetes 
mellitus. Pediatric diabetes 2010;11:424-430 
10. Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T: 
Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth 
with type 1 diabetes. Diabetes care 2007;30:2331-2337 
11. Perantie DC, Koller JM, Weaver PM, Lugar HM, Black KJ, White NH, Hershey T: Prospectively 
determined impact of type 1 diabetes on brain volume during development. Diabetes 2011;60:3006-
3014 
12. Auer RN, Wieloch T, Olsson Y, Siesjo BK: The distribution of hypoglycemic brain damage. Acta 
neuropathologica 1984;64:177-191 
13. Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA: Hypoglycemic neuronal death is triggered 
by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest 2007;117:910-918 
14. Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ: Diabetes increases brain damage caused by severe 
hypoglycemia. American journal of physiology Endocrinology and metabolism 2009;297:E194-201 
Page 34 of 48
For Peer Review Only
Diabetes
 14
15. Won SJ, Yoo BH, Kauppinen TM, Choi BY, Kim JH, Jang BG, Lee MW, Sohn M, Liu J, Swanson RA, 
Suh SW: Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial 
activation, and cognitive impairment in diabetic rats. Journal of neuroinflammation 2012;9:182 
16. Yamada KA, Rensing N, Izumi Y, De Erausquin GA, Gazit V, Dorsey DA, Herrera DG: Repetitive 
hypoglycemia in young rats impairs hippocampal long-term potentiation. Pediatr Res 2004;55:372-
379 
17. McNay EC, Williamson A, McCrimmon RJ, Sherwin RS: Cognitive and neural hippocampal effects 
of long-term moderate recurrent hypoglycemia. Diabetes 2006;55:1088-1095 
18. Puente EC, Silverstein J, Bree AJ, Musikantow DR, Wozniak DF, Maloney S, Daphna-Iken D, Fisher 
SJ: Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced 
by severe hypoglycemia. Diabetes 59:1055-1062 
19. Butterfield DA, Di Domenico F, Barone E: Elevated risk of type 2 diabetes for development of 
Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 2014;1842:1693-
1706 
20. Singh P, Jain A, Kaur G: Impact of hypoglycemia and diabetes on CNS: correlation of 
mitochondrial oxidative stress with DNA damage. Molecular and cellular biochemistry 2004;260:153-
159 
21. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM: Effects of acute insulin-
induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular 
disease in diabetes. Diabetes care 2010;33:1591-1597 
22. Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, Esposito K, Giugliano D: 
Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and 
increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 
diabetes. Diabetes 2012;61:2993-2997 
23. Dominguez C, Ruiz E, Gussinye M, Carrascosa A: Oxidative stress at onset and in early stages of 
type 1 diabetes in children and adolescents. Diabetes care 1998;21:1736-1742 
24. Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda 
G, Santini SA: Early increase of oxidative stress and reduced antioxidant defenses in patients with 
uncomplicated type 1 diabetes: a case for gender difference. Diabetes care 2002;25:370-375 
25. Vucic M, Gavella M, Bozikov V, Ashcroft SJ, Rocic B: Superoxide dismutase activity in lymphocytes 
and polymorphonuclear cells of diabetic patients. European journal of clinical chemistry and clinical 
biochemistry : journal of the Forum of European Clinical Chemistry Societies 1997;35:517-521 
26. Hayes JD, Dinkova-Kostova AT: The Nrf2 regulatory network provides an interface between redox 
and intermediary metabolism. Trends Biochem Sci 2014;39:199-218 
27. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford 
ML, Hayes JD: Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free radical biology & 
medicine 2010;48:357-371 
Page 35 of 48
For Peer Review Only
Diabetes
 15
28. Langston RF, Wood ER: Associative recognition and the hippocampus: differential effects of 
hippocampal lesions on object-place, object-context and object-place-context memory. 
Hippocampus 2010;20:1139-1153 
29. McNay EC, Fries TM, Gold PE: Decreases in rat extracellular hippocampal glucose concentration 
associated with cognitive demand during a spatial task. Proceedings of the National Academy of 
Sciences of the United States of America 2000;97:2881-2885 
30. Mihara M, Uchiyama M: Determination of malonaldehyde precursor in tissues by thiobarbituric 
acid test. Analytical biochemistry 1978;86:271-278 
31. Gorrini C, Harris IS, Mak TW: Modulation of oxidative stress as an anticancer strategy. Nature 
reviews Drug discovery 2013;12:931-947 
32. Jacob KD, Noren Hooten N, Trzeciak AR, Evans MK: Markers of oxidant stress that are clinically 
relevant in aging and age-related disease. Mechanisms of ageing and development 2013;134:139-
157 
33. Shenton D, Smirnova JB, Selley JN, Carroll K, Hubbard SJ, Pavitt GD, Ashe MP, Grant CM: Global 
translational responses to oxidative stress impact upon multiple levels of protein synthesis. J Biol 
Chem 2006;281:29011-29021 
34. McNay EC, Teske JA, Kotz CM, Dunn-Meynell A, Levin BE, McCrimmon RJ, Sherwin RS: Long-term, 
intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin 
resistance: a model for weight gain with intensive insulin therapy. Am J Physiol Endocrinol Metab 
2013;304:E131-138 
35. Rehni AK, Nautiyal N, Perez-Pinzon MA, Dave KR: Hyperglycemia / hypoglycemia-induced 
mitochondrial dysfunction and cerebral ischemic damage in diabetics. Metabolic brain disease 2014; 
36. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 
2005;54:1615-1625 
37. Russo VC, Higgins S, Werther GA, Cameron FJ: Effects of fluctuating glucose levels on neuronal 
cells in vitro. Neurochemical research 2012;37:1768-1782 
38. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB: Overexpression of manganese superoxide 
dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear 
transcription factor-kappaB and activated protein-1. The Journal of biological chemistry 
1998;273:13245-13254 
39. Nomura K, Imai H, Koumura T, Arai M, Nakagawa Y: Mitochondrial phospholipid hydroperoxide 
glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. The 
Journal of biological chemistry 1999;274:29294-29302 
40. Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T: Diabetic 
downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in 
cardiac cells in vitro and in vivo. Diabetes 2011;60:625-633 
Page 36 of 48
For Peer Review Only
Diabetes
 16
41. He HJ, Wang GY, Gao Y, Ling WH, Yu ZW, Jin TR: Curcumin attenuates Nrf2 signaling defect, 
oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World journal of 
diabetes 2012;3:94-104 
42. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD: 
Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and 
energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol 
Med 2015;88:108-146 
43. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD: The protective role of Nrf2 in streptozotocin-
induced diabetic nephropathy. Diabetes 2010;59:850-860 
44. Hamanaka RB, Chandel NS: Mitochondrial reactive oxygen species regulate cellular signaling and 
dictate biological outcomes. Trends Biochem Sci 2010;35:505-513 
45. Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y, Tan Y, Cui W, Liu B, Cui T, Epstein PN, Fu Y, Cai L: 
Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of 
proteasomal activities: roles of Nrf2 and NF-kappaB. Am J Physiol Heart Circ Physiol 2013;304:H567-
578 
46. Kraft AD, Lee JM, Johnson DA, Kan YW, Johnson JA: Neuronal sensitivity to kainic acid is 
dependent on the Nrf2-mediated actions of the antioxidant response element. Journal of 
neurochemistry 2006;98:1852-1865 
47. Long M, Rojo de la Vega M, Wen Q, Bharara M, Jiang T, Zhang R, Zhou S, Wong PK, Wondrak GT, 
Zheng H, Zhang DD: An Essential Role of NRF2 in Diabetic Wound Healing. Diabetes 2016;65:780-793 
 
 
 
 
Page 37 of 48
For Peer Review Only
Diabetes
 17
Figure 1. Physiological profile of diabetic and non-diabetic WT and Nrf2
-/-
 mice exposed 
to recurrent hypoglycemia. A and C: Body weight was comparable between experimental 
groups and unaltered by either genotype or recurrent hypoglycemia. B and D: Example of 
typical insulin induced hypoglycemic event in WT and Nrf2-/- animals with a comparable 
level of hypoglycemia achieved despite Nrf2-/- animals receiving significantly lower insulin 
doses (starting dose 0.75mU/g WT control vs. 0.5mU/g Nrf2-/- animals). Control (Con), Con 
+ Hypo, T1D and T1D + Hypo all n=8 per group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D 
Nrf2
-/- + Hypo all n=7-8 per group. Results represent mean values ± SEM. Data were 
analyzed by 2-way ANOVA with T1D and Hypo as between subject factors followed by 
Tukey’s post hoc test *p<0.05, **p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, 
♯♯p<0.01 Hypo vs. No Hypo.  
Figure 2. Recurrent hypoglycemia (Hypo) in T1D mice impairs cognitive performance 
in novel-object recognition (NOR) and Spontaneous Alternation tasks. A: Discrimination 
index (D3) demonstrating that T1D mice are significantly impaired when tested in the 24hr 
NOR task. This is exacerbated in T1D animals following Hypo. B: Mean 4/5 alternation 
performance on a closed arm plus maze, expressed as a percentage of possible alternations is 
significantly reduced in T1D animals following Hypo. C: Nrf2
-/-
 and T1D Nrf2
-/-
 mice 
following Hypo were significantly impaired when tested in the 24hr NOR task, and D: Mean 
4/5 alternation performance on a closed arm plus maze, expressed as a percentage of possible 
alternations is significantly reduced in Nrf2-/-+ Hypo and T1D Nrf2-/-+ Hypo animals when 
compared to their control (no hypo) counterparts. Control (Con), Con + Hypo, T1D and T1D 
+ Hypo all n=8 per group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- + Hypo all n=7-
8 per group. Results represent mean values ± SEM. Data were analyzed by 2-way ANOVA 
with T1D and Hypo as between subject factors followed by Tukey’s post hoc test *p<0.05 
Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo  
Figure 3. Recurrent hypoglycemia in T1D is associated with increased markers of 
oxidative damage. The levels of lipid peroxidation were determined using the thiobarbituric 
acid reactive substances (TBARS) assay and protein carbonylation by ELISA. A: The levels 
of lipid peroxidation and B: protein carbonylation were significantly elevated following Hypo 
and further enhanced in T1D mice. The levels of C. Lipid peroxidation and D: protein 
carbonylation were augmented following Hypo in Nrf2
-/-
 mice and enhanced further in T1D 
Nrf2
-/-
 + Hypo animals. Control (Con), Con + Hypo, T1D and T1D + Hypo all n=8 per group. 
Nrf2
-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- + Hypo all n=7-8 per group. Results 
represent mean values ± SEM. Data were analyzed by 2-way ANOVA with T1D and Hypo as 
between subject factors followed by Tukey’s post hoc test  *p<0.05 Control or Nrf2-/-vs T1D 
or T1D Nrf2-/-,  ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo. 
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Tables 1. Recurrent hypoglycemia and T1D in both Wild-type and Nrf2
-/-
 mice is associated with modulation of genes involved in mediating anti-
oxidant and redox systems. mRNA was extracted and processed for real-time PCR to evaluate changes in gene expression of Hemeoxygenase 1 (Hmox1), 
Nrf2, NAD(P)H:quinoneoxidoreductase (Nqo1), Thioredoxinreductase 1 (Txnrd1), Sulfiredoxin 1 (Srxn1), Thioredoxin 1  (Txn1) and GlutathioneS-
transferase Alpha subunit 1 (Gsta1). Control (Con), Con + Hypo, T1D and T1D + Hypo all n=8 per group. Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/- 
+ Hypo all n=7-8 per group. Results represent mean values ± SEM. Data were analyzed within genotype by 2-way ANOVA with T1D and Hypo as between 
subject factors followed by Tukey’s post hoc test *p<0.05, **p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo 
Gene Control Control + 
Hypo 
T1D T1D + Hypo  Nrf2-/- Nrf2-/- 
+ Hypo 
T1D Nrf2
-/- T1D Nrf2-/- 
+ Hypo 
Hmox-1 1.00±0.28 1.15±0.14 1.34±0.14* 1.88±0.55*
♯  0.71±0.07 0.49±0.08 1.05±0.11** 1.15±0.11**♯ 
Nrf2 1.00±0.15 1.14±0.18 1.86±0.18* 12.13±0.10*
♯  n/d n/d n/d n/d 
Nqo1 1.00±0.35 1.53±0.17 2.11±0.28* 3.20±0.44*
♯  1.94±0.13 1.78±0.12 2.18±0.31* 2.74±0.24*♯ 
Txnrd1 1.00±0.19 1.07±0.10 1.08±0.10 1.09±0.13  0.79±0.05 0.95±0.12 0.60±0.08 0.59±0.05 
Srxn1 1.00±0.09 0.94±0.06 1.06±0.03 1.13±0.14  0.58±0.10 0.71±0.16 0.43±0.05 0.48±0.04 
Txn1 1.00±0.16 0.96±0.11 1.28±0.19 1.32±0.23  0.82±0.06 0.74±0.11 0.73±0.11 0.76±0.11 
Gsta1 1.00±0.13 0.50±0.76
♯ 1.00±0.06 0.53±0.16♯  0.11±0.04 0.22±0.07 0.10±0.04 0.10±0.04 
 
Page 39 of 48
For Peer Review Only
Diabetes
 19
 
Table 2. Recurrent hypoglycemia and T1D induce inflammation within the hippocampus in both WT T1D animals and Nrf2
-/-
animals respectively. 
Levels of a number of common inflammatory cytokines were measured within hippocampal homogenates by ELISA. Con, Con + Hypo, T1D and T1D + 
Hypo all n=8 per group.  Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/-+ Hypo all n=7-8 per group.  Results represent mean values ± SEM. Data were 
analyzed within genotype by 2-way ANOVA with T1D and Hypo as between subject factors followed by Tukey’s post hoc test * p<0.05, test *p<0.05, 
**p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo. 
Protein 
(pg/mg) 
Control Control + 
Hypo 
T1D T1D + Hypo  Nrf2-/- Nrf2-/- 
+ Hypo 
T1D Nrf2
-/- T1D Nrf2-/- 
+ Hypo 
IFNg 1.26±0.19 1.01±0.19 1.21±0.19 1.16±0.29  2.04 ±0.13 1.99±0.24 1.97±0.21 1.73±0.30 
KC/GRO 57.60±7.42 68.86±10.73 65.15±9.51 59.57±7.03  99.49±7.24 95.35±12.47 102.7±12.12 116.7±21.47 
IL-1b 1.63±0.14 1.72±0.26 2.68±0.25** 3.15±0.43**
♯  2.96±0.49 2.62±0.39 6.95±0.80* 9.40±1.23*♯ 
IL-2 5.20±1.10 6.19±0.93 6.80±1.27* 10.72±1.23*
♯  6.47±0.76 7.10±1.10 10.91±1.15** 10.88±0.86**♯ 
TNFa 1.87±0.45 1.39±0.73 4.28±0.44* 7.37±0.61**
♯  4.97±0.86 7.34±1.40 10.41±2.28* 10.75±1.98*♯ 
IL-4 1.56±0.26 1.32±0.26 3.05±0.52** 4.35±0.34**
♯  2.16±0.32 3.28±0.53 4.96±0.58** 5.34±0.57**♯ 
IL-6 85.54±13.29 106.4±16.11 146.8±17.30** 178.3±9.32**
♯  99.48±11.59 140.4±3.99♯ 145.4±8.58** 149.6±6.88**♯ 
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IL-12p70 20.20±1.31 25.84±1.15
♯ 24.83±1.71 27.65±02.09*♯  20.00±3.25 27.63±2.83♯♯ 22.02±3.84* 35.23±4.27*♯♯ 
IL-5 5.39±0.68 7.17±0.41
♯ 5.11±0.69 8.48±0.74*♯♯  5.48±0.66 6.78±0.31♯ 8.45±0.59** 7.58±0.22**♯ 
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Figure 2 
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Figure 3 
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 Supplementary Figure 1. Time line and weight profile of control and T1D WT and Nrf2-/- mice exposed to 
recurrent hypoglycemia. A. Timeline for induction of diabetes, surgery, recurrent hypoglycemia, behavioral testing and 
biochemical analysis. B. Body weight was comparable between groups and unaltered by either genotype or RH. Results 
represent mean values ± SEM.  
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Supplementary Table 1. Details of Applied Biosystems TaqMan® gene expression assays used for real-time PCR analysis.  
Gene Applied Biosystems assay ID 
Hmox-1 Mm00516005_m1 
Nrf2 Mm00477784_m1 
Nqo1 Mm01253561_m1 
IL-6 Mm00446190_m1 
Tnfa Mm00443260_g1  
IL-1b Mm00434228_m1 
Nos2 Mm00440502_m1 
Txnrd1 Mm00443675_m1 
Srxn1 Mm00769566_m1  
Txn1 Mm00726847_s1 
Gsta1 Hs00275575_m1 
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Supplementary Table 2. Recurrent hypoglycemia and T1D enhance the expression of inflammatory genes within the hippocampus in 
WT and Nrf2
-/- 
mice. mRNA was extracted and processed for real-time PCR to evaluate changes in gene expression Interleukin 6 (IL-6), Tumor 
necrosis factor alpha (Tnf-α), Interleukin -1beta (IL−1β) and Inducible nitric oxide synthase (Nos2). Con, Con + Hypo, T1D and T1D + Hypo 
all n=8 per group.  Nrf2-/-, Nrf2-/-+ Hypo, T1D Nrf2-/- and T1D Nrf2-/-+ Hypo all n=7-8 per group.  Results represent mean values ± SEM. Data 
were analyzed within genotype by 2-way ANOVA with T1D and Hypo as between subject factors followed by Tukey’s post hoc test * p<0.05, 
test *p<0.05, **p<0.01 Control or Nrf2-/-vs T1D or T1D Nrf2-/-, ♯p<0.05, ♯♯p<0.01 Hypo vs. No Hypo. 
Gene Control Control + 
Hypo 
T1D T1D + 
Hypo 
Nrf2
-/- Nrf2-/- 
+ Hypo 
T1D Nrf2
-/- T1D Nrf2-/- 
+ Hypo 
IL-6 1.00±0.20 1.13±0.20 1.98±0.37 2.94±0.43 0.88±0.09 0.51±0.03 1.27±0.17** 1.66±0.03** 
Tnfa 1.00±0.18 1.23±0.32 1.87±0.24 3.02±0.48 0.79±0.04 0.87±0.07 1.45±0.15** 1.50±0.20** 
IL-1b 1.00±0.31 0.70±0.08 0.95±0.13 0.98±0.14 0.17±0.02 0.15±0.02 0.24±0.02** 0.30±0.06** 
Nos2 1.00±0.28 1.57±0.33 1.47±0.24 2.79±0.46 0.17±0.02 0.15±0.02 0.245±0.02** 0.30±0.06** 
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